External Validation of a Risk Score to Predict Intravenous Immunoglobulin Resistance in Patients With Kawasaki Disease
Authors:
- Tohru KobayashiTKTohru Kobayashi
- Tomio KobayashiTKTomio Kobayashi
- Akihiro MorikawaAMAkihiro Morikawa
- Tetsuya OtaniTOTetsuya Otani
- Kazuo TakeuchiKTKazuo Takeuchi
- Mamoru AyusawaMAMamoru Ayusawa
- Keiji TsuchiyaKTKeiji Tsuchiya
- Kenji YasudaKYKenji Yasuda
- Takahiro SuzukiTSTakahiro Suzuki
- Shinya ShimoyamaSSShinya Shimoyama
- Kentaro IkedaKIKentaro Ikeda
- 1 February 2011
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 30 (2) , 145-147
Abstract
We previously developed a new risk score to predict intravenous immunoglobulin (IVIG) resistance in Kawasaki disease. However, the IVIG dosage used in that study (1 g/kg/d for 2 consecutive days) differs from the single infusion of 2 g/kg recommended in the United States and elsewhere. Our aim was to assess the validity and applicability of our risk score in patients treated with a single infusion. We used a database of 1626 patients with Kawasaki disease given initial IVIG treatment at a dose of 1 g/kg/d for 2 consecutive days (n = 990; IVIG- 1 g/kg × 2) or 2 g/kg/d for 1 day (n = 636; IVIG- 2 g/kg × 1) across 17 hospitals in Japan. Patients received the total IVIG dose within 36 hours in IVIG- 1 g/kg × 2 and 24 hours in IVIG- 2 g/kg × 1. We stratified the patients according to a risk scoring system developed to predict IVIG unresponsiveness, based on scores of ≥5 points. We compared the accuracy of prediction between the 2 groups using receiver operating characteristic analysis. Baseline characteristics and clinical outcomes were similar between both groups. The areas under the receiver operating characteristic curve in IVIG- 2 g/kg × 1 were similar to those of IVIG- 1 g/kg × 2. Using a cut-off risk score of ≥5 points, we could identify IVIG resistance in terms of coronary artery abnormalities within 1 month and coronary artery abnormalities at 1 month with equivalent sensitivity and specificity in both groups. Our risk score can be used to predict IVIG unresponsiveness to a regimen based on a single infusion of 2 g/kg IVIG.Keywords
This publication has 12 references indexed in Scilit:
- Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki DiseaseCirculation, 2006
- Infliximab treatment for refractory Kawasaki syndromeThe Journal of Pediatrics, 2005
- Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)Pediatrics International, 2005
- Kawasaki syndromeThe Lancet, 2004
- Corticosteroids in the initial treatment of Kawasaki disease: Report of a randomized trialThe Journal of Pediatrics, 2003
- Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki DiseasePediatrics, 2000
- Corticosteroids in the treatment of the acute phase of Kawasaki diseaseThe Journal of Pediatrics, 1999
- Intravenous gamma-globulin treatment and retreatment in Kawasaki diseaseThe Pediatric Infectious Disease Journal, 1998
- Long-term Consequences of Kawasaki DiseaseCirculation, 1996
- A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki SyndromeNew England Journal of Medicine, 1991